7th CACHEXIA Conference

7th CACHEXIA
Conference

Monday, December 9, 2013
13:30 - 15:30 - OPENING SESSION
Muscle Wasting – Assessment & Epidemiology
“Hippocrates” clinical science key note lecture: Assessing muscle
mass – brief history and state of the art
Stephen Heymsfield , Baton Rouge, USA
Muscle mass and survival: the epidemiologic viewpoint
Kamyar Kalantar-Zadeh, Los Angeles, USA
Psychosocial effect of cachexia
Jane Hopkinson, Cardiff , UK
Frailty: international consensus and its role in sarcopenia and cachexia
John E Morley, St. Louis, USAThe obesity paradox in 2013 – the stroke example
Wolfram Doehner, Berlin, Germany

15:30 - 16:00 - Coffee break
16:00 - 17:45 - PLENARY SESSION
Muscle Wasting – New Therapeutic Approaches“Prometheus” basic science key note lecture:
Ghrelin – from discovery to therapy
Masayasu Kojima, Kurume, Japan
Targeting MIC-1/GDF1Samuel Breit, Sydney, Australia
Muscle regeneration & miRNAs
Thomas Thum, Hannover, Germany
Biomarkers for skeletal muscle wasting – international consensus
Emanuele Marzetti, Rome, Italy

18:00 - 19:15 - Welcome reception and poster viewing11:00 - 12:30 - BASIC TRACK
Muscle basic science
Signaling pathways that mediate sarcopenia andcachexia - 2013 update.
The mitochondrial contribution to muscle atrophy in aging
and disease
Yi-Fan Chen, Taichung, Taiwan
The role of differentiation as causal factor in cancer-induced
muscle wasting
Denis Guttridge, Columbus, USA
Proteolysis mechanisms – an update
Didier Attaix, Clermont-Ferrand, France
Muscle and non-muscle tissue interactions in cachexia:
the role of inflammation
Josep Argiles, Barcelona, Spain
Panel discussion «Perspectives of research»

11:00 - 12:30 - CLINICAL TRACK
Oncology and cancer cachexia
Impact of cancer cachexia on oncology outcomes and anticancer treatment
Florian Strasser, St. Gallen, Switzerland
Multi-modal therapy for a multimodal problem: the MENAC study
Ken Fearon, Edinburgh, UK
Diagnostic criteria of cancer cachexia: a critical evaluation
Vickie Baracos, Edmonton, Canada
Cardiovascular problems and autonomic dysfunction in cancer cachexia
Jochen Springer, Berlin, Germany
Nutritional intervention in cancer cachexia
Nicolaas Deutz, College Station, USA

12:45 - 13:45 - Sponsored lunch seminarsTuesday, December 10, 201307:15 - 08:15 - Sponsored breakfast seminars
08:30 - 10:00 - CLINICAL TRACK

Kobe/Osaka JAPAN

9-11 December 2013
Abstract submissions are welcome> Deadline September 30, 2013
> Poster presentation> Poster awards> Young investigator awards> Plenty of time for discussion

For further information visit

www.cachexia.org

Skeletal muscle mass & chronic illness
New methods to assess skeletal muscle mass changes
William Evans, Research Triangle Park, USA
The interface between fat and muscle in late life sarcopenia & cachexia
Tamara Harris, Bethesda, USACachexia in CHF and COPD: similarities and differences
Annemie Schols, Maastricht, the Netherlands
Respiratory muscles mass and function & COPD exacerbation
Mike Polkey, London, UK
Muscle wasting, exercise and hip fracture
Maria Fiatarone Singh, Sydney, Australia
Why are so many companies studying inclusion body myositis?

08:30 - 10:00 - BASIC TRACK
From food intake to ghrelin and sarcopenia
Alterations in the Ghrelin/NPY axis in anorexia and cachexia
Herbert Herzog, Sydney, Australia
Etanercept for cachexia in rheumatoid arthritis: roles of gut hormonesand leptin
Chih-Yen Chen, Taipei , Taiwan
The herbal medicine rikkunshito in cancer anorexia-cachexia: impact
on survival and relationship to ghrelin signaling
Akihiro Asakawa, Kagoshima, Japan
Modulation of hunger and satiety peptide activity by plasma
immunoglobulins
Serguei Fetissov, Rouen, France
Sarcopenic obesity
Kyung Mook Choi, Seoul, Korea

10:00 - 11:00 - Coffee break & poster sessions

14:00 - 15:30 - CLINICAL TRACK
Drug treatment options and results update
SARMs
Ghrelin
Targeting myostatin & activin receptors
Novel beta-blockers
Panel discussion

14:00 - 15:30 - JUDGES’ CHOICE
Oral presentations of selected abstracts

15:30 - 16:30 - Coffee break and poster sessions
16:30 - 18:00 - CLINICAL TRACK
Late breaking clinical trials and biomarker
research

16:30 - 18:00 - BASIC TRACK

Preliminary PROGRAM
Wednesday, December 11, 2013
08:00 - 09:30 - Young investigators
Awards Session - Clinical & Basic
3 basic science and 3 clinical research presentations
to be short-listed

08:00 - 09:30 - CLINICAL & BASIC TRACKSFood intake, appetite and nutrition
Effects of melatonin on appetite and other symptoms in cancer cachexia
Edigio Del Fabbro, Richmond, USA
Screening questionnaires for malnutrition and sarcopenia
Ted Malmstrom, St. Louis, USA
Mechanisms of anorexia
Johan Ruud, Linköping, Sweden
Anorexia and quality of life
Alessandro Laviano, Rome, Italy
Nutrition in drug trials – problems & opportunities
Jürgen Bauer, Nuremberg, Germany

09:30 - 10:30 - Coffee break & poster sessions
10:30 - 12:00 - JUDGES' CHOICE
Oral presentations of selected abstracts(clinical & nutrition science)

10:30 - 12:00 - BASIC TRACK
Central mechanisms of cachexia
Rodent models of cachexia: predict power for clinical trials
Daniel Marks, Portland, USAThe role of the brain stem: autonomic dysfunction
Massimo Piepoli, Piacenza, Italy
Central mechanisms of appetite & fatigue
John E Morley, St. Louis, USA
Abnormal reflex systems in cachexia
Ewa Jankowska, Wroclaw, Poland

12:15 - 13:15 - Sponsored lunch seminars
13:30 - 15:00 - PLENARY SESSION
Developing therapies for cachexia & sarcopenia
The role of blood based biomarkers for muscle wasting treatment trials
Marc Hellerstein, Berkeley, USA
Remote monitoring of body weight, fluid status and physical activity:
telemedicine for cachexia & sarcopenia?
Friedrich Köhler, Berlin, Germany
What should usual care for nutrition be in cachexia trials?
Aminah Jatoi, Rochester, USA
What are approvable endpoints in cachexia & sarcopenia?
Stefan Anker, Berlin, Germany
The regulators comments
Giuseppe Rosano, London, UK
Panel discussion

Metabolic syndrome, biomarkers and bodywasting

15:00 - 15:30 - Coffee breakCachexia in chronic kidney disease
Robert Mak, La Jolla, USA
Muscle wasting in diabetesAntonio Zorzano, Barcelona, Spain
Diabetes mellitus and muscle wasting
Seok Won Park, Seoul, Korea
New biomarkers for skeletal muscle wasting in chronic illness
Stephan von Haehling, Berlin, Germany
Brown fat in cachexia
Graham Robertson, Concord, Australia

15:30 - 16:30 - PLENARY SESSION

19:30 - CONFERENCE DINNER

AWAR D S C E RE M O NY

Congress highlights
Basic Science
Denis Guttridge, Columbus, USA
Sarcopenia
Mitja Lainscak, Golnik, Slovenia
Nutritional Therapies
Maurizio Muscaritoli, Rome, Italy
Treatment of cachexia
Andrew Coats, Melbourne, Australia

7th CACHEXIA Conference

7th CACHEXIA
Conference

Monday, December 9, 2013
13:30 - 15:30 - OPENING SESSION
Muscle Wasting – Assessment & Epidemiology
“Hippocrates” clinical science key note lecture: Assessing muscle
mass – brief history and state of the art
Stephen Heymsfield , Baton Rouge, USA
Muscle mass and survival: the epidemiologic viewpoint
Kamyar Kalantar-Zadeh, Los Angeles, USA
Psychosocial effect of cachexia
Jane Hopkinson, Cardiff , UK
Frailty: international consensus and its role in sarcopenia and cachexia
John E Morley, St. Louis, USAThe obesity paradox in 2013 – the stroke example
Wolfram Doehner, Berlin, Germany

15:30 - 16:00 - Coffee break
16:00 - 17:45 - PLENARY SESSION
Muscle Wasting – New Therapeutic Approaches“Prometheus” basic science key note lecture:
Ghrelin – from discovery to therapy
Masayasu Kojima, Kurume, Japan
Targeting MIC-1/GDF1Samuel Breit, Sydney, Australia
Muscle regeneration & miRNAs
Thomas Thum, Hannover, Germany
Biomarkers for skeletal muscle wasting – international consensus
Emanuele Marzetti, Rome, Italy

18:00 - 19:15 - Welcome reception and poster viewing

11:00 - 12:30 - BASIC TRACK
Muscle basic science
Signaling pathways that mediate sarcopenia andcachexia - 2013 update.
The mitochondrial contribution to muscle atrophy in aging
and disease
Yi-Fan Chen, Taichung, Taiwan
The role of differentiation as causal factor in cancer-induced
muscle wasting
Denis Guttridge, Columbus, USA
Proteolysis mechanisms – an update
Didier Attaix, Clermont-Ferrand, France
Muscle and non-muscle tissue interactions in cachexia:
the role of inflammation
Josep Argiles, Barcelona, Spain
Panel discussion «Perspectives of research»11:00 - 12:30 - CLINICAL TRACK
Oncology and cancer cachexia
Impact of cancer cachexia on oncology outcomes and anticancer treatment
Florian Strasser, St. Gallen, Switzerland
Multi-modal therapy for a multimodal problem: the MENAC study
Ken Fearon, Edinburgh, UK
Diagnostic criteria of cancer cachexia: a critical evaluation
Vickie Baracos, Edmonton, Canada
Cardiovascular problems and autonomic dysfunction in cancer cachexia
Jochen Springer, Berlin, Germany
Nutritional intervention in cancer cachexia
Nicolaas Deutz, College Station, USA

12:45 - 13:45 - Sponsored lunch seminars

Tuesday, December 10, 201307:15 - 08:15 - Sponsored breakfast seminars
08:30 - 10:00 - CLINICAL TRACK

Kobe/Osaka JAPAN

9-11 December 2013
Abstract submissions are welcome> Deadline September 30, 2013
> Poster presentation> Poster awards> Young investigator awards> Plenty of time for discussion

For further information visit

www.cachexia.org

Skeletal muscle mass & chronic illness
New methods to assess skeletal muscle mass changes
William Evans, Research Triangle Park, USA
The interface between fat and muscle in late life sarcopenia & cachexia
Tamara Harris, Bethesda, USACachexia in CHF and COPD: similarities and differences
Annemie Schols, Maastricht, the Netherlands
Respiratory muscles mass and function & COPD exacerbation
Mike Polkey, London, UK
Muscle wasting, exercise and hip fracture
Maria Fiatarone Singh, Sydney, Australia
Why are so many companies studying inclusion body myositis?

08:30 - 10:00 - BASIC TRACK
From food intake to ghrelin and sarcopenia
Alterations in the Ghrelin/NPY axis in anorexia and cachexia
Herbert Herzog, Sydney, Australia
Etanercept for cachexia in rheumatoid arthritis: roles of gut hormones
and leptin
Chih-Yen Chen, Taipei , Taiwan
The herbal medicine rikkunshito in cancer anorexia-cachexia: impact
on survival and relationship to ghrelin signaling
Akihiro Asakawa, Kagoshima, Japan
Modulation of hunger and satiety peptide activity by plasma
immunoglobulins
Serguei Fetissov, Rouen, France
Sarcopenic obesity
Kyung Mook Choi, Seoul, Korea

10:00 - 11:00 - Coffee break & poster sessions

14:00 - 15:30 - CLINICAL TRACK
Drug treatment options and results update
SARMs
Ghrelin
Targeting myostatin & activin receptors
Novel beta-blockers
Panel discussion

14:00 - 15:30 - JUDGES’ CHOICE
Oral presentations of selected abstracts

15:30 - 16:30 - Coffee break and poster sessions
16:30 - 18:00 - CLINICAL TRACK
Late breaking clinical trials and biomarker
research

16:30 - 18:00 - BASIC TRACK

Preliminary PROGRAM
Wednesday, December 11, 2013
08:00 - 09:30 - Young investigators
Awards Session - Clinical & Basic
3 basic science and 3 clinical research presentations
to be short-listed

08:00 - 09:30 - CLINICAL & BASIC TRACKSFood intake, appetite and nutrition
Effects of melatonin on appetite and other symptoms in cancer cachexia
Edigio Del Fabbro, Richmond, USA
Screening questionnaires for malnutrition and sarcopenia
Ted Malmstrom, St. Louis, USA
Mechanisms of anorexia
Johan Ruud, Linköping, Sweden
Anorexia and quality of life
Alessandro Laviano, Rome, Italy
Nutrition in drug trials – problems & opportunities
Jürgen Bauer, Nuremberg, Germany

09:30 - 10:30 - Coffee break & poster sessions
10:30 - 12:00 - JUDGES' CHOICE
Oral presentations of selected abstracts(clinical & nutrition science)

10:30 - 12:00 - BASIC TRACKCentral mechanisms of cachexia
Rodent models of cachexia: predict power for clinical trials
Daniel Marks, Portland, USA
The role of the brain stem: autonomic dysfunction
Massimo Piepoli, Piacenza, Italy
Central mechanisms of appetite & fatigue
John E Morley, St. Louis, USA
Abnormal reflex systems in cachexia
Ewa Jankowska, Wroclaw, Poland

12:15 - 13:15 - Sponsored lunch seminars
13:30 - 15:00 - PLENARY SESSION
Developing therapies for cachexia & sarcopenia
The role of blood based biomarkers for muscle wasting treatment trials
Marc Hellerstein, Berkeley, USA
Remote monitoring of body weight, fluid status and physical activity:
telemedicine for cachexia & sarcopenia?
Friedrich Köhler, Berlin, Germany
What should usual care for nutrition be in cachexia trials?
Aminah Jatoi, Rochester, USA
What are approvable endpoints in cachexia & sarcopenia?
Stefan Anker, Berlin, Germany
The regulators comments
Giuseppe Rosano, London, UK
Panel discussion

Metabolic syndrome, biomarkers and bodywasting

15:00 - 15:30 - Coffee breakCachexia in chronic kidney disease
Robert Mak, La Jolla, USA
Muscle wasting in diabetes
Antonio Zorzano, Barcelona, Spain
Diabetes mellitus and muscle wasting
Seok Won Park, Seoul, Korea
New biomarkers for skeletal muscle wasting in chronic illness
Stephan von Haehling, Berlin, Germany
Brown fat in cachexia
Graham Robertson, Concord, Australia

15:30 - 16:30 - PLENARY SESSION

19:30 - CONFERENCE DINNER

AWAR D S C E RE M O NY

Congress highlights
Basic Science
Denis Guttridge, Columbus, USA
Sarcopenia
Mitja Lainscak, Golnik, Slovenia
Nutritional Therapies
Maurizio Muscaritoli, Rome, Italy
Treatment of cachexia
Andrew Coats, Melbourne, Australia